Literature DB >> 20410880

Scintigraphic biomarkers for colonic dysmotility.

M Camilleri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20410880      PMCID： PMC3196563          DOI： 10.1038/clpt.2010.23

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  31 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.

Authors:  C M Prather; M Camilleri; A R Zinsmeister; S McKinzie; G Thomforde
Journal:  Gastroenterology       Date:  2000-03       Impact factor: 22.682

3.  Emptying of the terminal ileum in intact humans. Influence of meal residue and ileal motility.

Authors:  R C Spiller; M L Brown; S F Phillips
Journal:  Gastroenterology       Date:  1987-03       Impact factor: 22.682

4.  Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.

Authors:  E P Bouras; M Camilleri; D D Burton; G Thomforde; S McKinzie; A R Zinsmeister
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

5.  Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.

Authors:  Michael Camilleri; Elena Atanasova; Paula J Carlson; Umraan Ahmad; H Jae Kim; Blanca E Viramontes; Sanna McKinzie; Raul Urrutia
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

6.  Performance characteristics of scintigraphic transit measurements for studies of experimental therapies.

Authors:  F Cremonini; B P Mullan; M Camilleri; D D Burton; M R Rank
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

7.  Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.

Authors:  M Delvaux; A Beck; J Jacob; H Bouzamondo; F T Weber; J Frexinos
Journal:  Aliment Pharmacol Ther       Date:  2004-07-15       Impact factor: 8.171

8.  Neurotrophin-3 improves functional constipation.

Authors:  Henry P Parkman; Satish S C Rao; James C Reynolds; Lawrence R Schiller; Arnold Wald; Philip B Miner; Anthony J Lembo; James M Gordon; Douglas A Drossman; Lynn Waltzman; Nancy Stambler; Jesse M Cedarbaum
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

9.  Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

Authors:  Seth Sweetser; Michael Camilleri; Sara J Linker Nord; Duane D Burton; Lorna Castenada; Robert Croop; Gary Tong; Randy Dockens; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-02       Impact factor: 4.052

10.  Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.

Authors:  M R von der Ohe; M Camilleri; L K Kvols; G M Thomforde
Journal:  N Engl J Med       Date:  1993-10-07       Impact factor: 91.245
View more
  24 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

Review 2.  Methods for the assessment of small-bowel and colonic transit.

Authors:  Lawrence A Szarka; Michael Camilleri
Journal:  Semin Nucl Med       Date:  2012-03       Impact factor: 4.446

3.  Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.

Authors:  Banny S Wong; Michael Camilleri; Paula J Carlson; Suwebatu Odunsi-Shiyanbade; Sanna McKinzie; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Dis Sci       Date:  2012-01-21       Impact factor: 3.199

4.  Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

Authors:  B S Wong; M Camilleri; D Eckert; P Carlson; M Ryks; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2012-01-30       Impact factor: 3.598

5.  Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.

Authors:  M Camilleri; M I Vazquez-Roque; P Carlson; D Burton; B S Wong; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2011-08-24       Impact factor: 3.598

Review 6.  More movement with evaluating colonic transit in humans.

Authors:  Adil E Bharucha; Bradley Anderson; Michel Bouchoucha
Journal:  Neurogastroenterol Motil       Date:  2019-02       Impact factor: 3.598

Review 7.  Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.

Authors:  Nelson Valentin; Andres Acosta; Michael Camilleri
Journal:  Expert Opin Investig Drugs       Date:  2015-06       Impact factor: 6.206

8.  Drug pipeline is flush with new options for chronic constipation.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

9.  Irritable bowel syndrome: how useful is the term and the 'diagnosis'?

Authors:  Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

10.  Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice.

Authors:  G J Kolar; M Camilleri; D Burton; A Nadeau; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2013-10-10       Impact factor: 3.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.